Vimarsana
Biggest News Aggregation in the World

Page 3 - Axi Cel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axi Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axi Cel Today - Breaking & Trending Today

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL - Vimarsana News

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

Study Examines Axi-Cel Use for Follicular Lymphoma Management - Vimarsana News

Study Examines Axi-Cel Use for Follicular Lymphoma Management

Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel.

Source: ajmc.com
Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL - Vimarsana News

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).

Source: ajmc.com